Our research projects

  • A translational approach to optimisation of antimicrobial therapy for critically ill patients that prevents the emergence of ‘Superbugs’
  • Optimise dosing of commonly used beta-lactam antibiotics in intensive care unit patients so as to maximise therapeutic efficacy and improve patient outcomes
  • Intravenous dose optimisation of fosfomycin and amikacin in multi-drug resistant Gram negative pneumonia
  • Optimization of alternative antibiotic dosing regimens for maximal antibacterial effect and suppression of resistance
  • Pharmacodynamics of intravenous aminoglycosides

 

Study with us

Using laboratory-based infection models to develop better antibiotic dosing regimens

A domestic PhD scholarship is available from the NHMRC-funded Centre of Research Excellence in Redefining Antimicrobial Use to Reduce Resistance - CRE REDUCE - for a motivated and independent healthcare practitioner or scientist to use state-of-the-art laboratory based infection models to develop a better understanding of dosing regimens that can maximise bacterial killing and suppress the emergence of antibiotic resistance.

This PhD will seek to describe the antibiotic concentrations associated with maximal antibiotic effects and will provide the opportunity for the student to learn advanced pharmacokinetic and pharmacodynamic modelling skills as well as develop skills in project design and management. Ideally the applicant should hold an Honours or Master’s degree with adequate previous research experience. 

Read more

 

Industry lead projects

Cardeas Pharma Corp

Project title: A dynamic in vitro hollow-fiber infection model investigation of the pharmacokinetics/pharmacodynamics of amikacin and fosfomycin mono- and combination therapy against two different inocula of Pseudomonas aeruginosa and Klebsiella pneumoniae

Publication resulting from the project:

Sime, Fekade Bruck, Johnson, Adam, Whalley, Sarah, Santoyo-Castelazo, Anahi, Montgomery, A. Bruce, Walters, Kathie Ann, Lipman, Jeffrey , Hope, William W. and Roberts, Jason A. (2017) Pharmacodynamics of aerosolized fosfomycin and amikacin against resistant clinical isolates of Pseudomonas aeruginosa and Klebsiella pneumoniae in a hollow-fiber infection model: experimental basis for combination therapy. Antimicrobial Agents and Chemotherapy, 61 1: . doi:10.1128/AAC.01763-16

The Medicines Company

Project title: An Ex Vivo Study of Meropenem - Vaborbactam Clearance by Hemofiltration